Early intervention is critical in order to delay or prevent dementia
In the long human search for ways to hold the mind together as it ages, Australian researchers have offered a quiet but meaningful signal: a herbal compound drawing on ginseng, ginkgo, and saffron improved memory and mental flexibility in older adults with mild cognitive impairment over twelve weeks. The finding matters not only for what it shows, but for what it addresses — a condition affecting hundreds of millions of people worldwide for which no approved medicine yet exists. Science, here, is not announcing a cure but opening a door worth walking through carefully.
- Mild cognitive impairment — the fragile threshold between normal aging and dementia — affects 17% of people over 60 globally, yet no approved treatment exists to slow its progression.
- A 12-week Australian clinical trial found that participants taking the herbal extract Sailuotong showed statistically significant gains in delayed memory recall and executive function compared to those on placebo.
- The compound, blending Panax ginseng, Ginkgo biloba, and saffron, is believed to work through several pathways at once — reducing inflammation, fighting oxidative stress, and boosting the brain's acetylcholine activity.
- The trial was small and short, and researchers caution that improved test scores have not yet been shown to translate into better daily functioning or long-term dementia prevention.
- The team is now pursuing funding for a larger, longer study — the real test of whether SLT can do what no drug currently can: meaningfully delay the onset of dementia.
Researchers at Western Sydney University have completed what they describe as Australia's first clinical trial of a herbal extract aimed at slowing cognitive decline in older adults. The compound — Sailuotong, or SLT — produced measurable improvements in memory and mental flexibility among people with mild cognitive impairment, the condition that sits between normal aging and dementia and carries a fivefold increased risk of progressing further.
The 12-week double-blind study enrolled 78 participants aged 60 and older. Half received 180 milligrams of SLT daily; half received a placebo. Those on SLT showed significant improvements in delayed memory recall and in executive function — the mental agility involved in switching tasks and managing complex demands. The extract was well-tolerated, with few adverse events.
SLT is a standardized preparation combining Panax ginseng, Ginkgo biloba, and saffron, developed through a partnership between Sydney's NICM Health Research Institute and Beijing's Xiyuan Hospital. It is thought to work through multiple mechanisms: reducing inflammation, countering oxidative stress, protecting cells, and enhancing acetylcholine — a neurotransmitter central to memory and attention.
The stakes are considerable. Mild cognitive impairment has no approved pharmaceutical treatment, yet it affects roughly 17 percent of people over 60 worldwide. Lead researcher Associate Professor Genevieve Steiner-Lim called early intervention critical to delaying or preventing a dementia diagnosis — making even a 12-week improvement noteworthy.
The team is candid about the trial's limits: it was small, brief, and measured test performance rather than real-world functioning. Whether SLT helps people manage daily life more independently remains unknown. Researchers are now seeking funding for a larger, longer study. For now, SLT is a promising candidate — not yet a treatment, but a direction worth pursuing with care.
Researchers at Western Sydney University have completed what they describe as Australia's first clinical trial of a herbal extract designed to slow cognitive decline in older adults. The compound, called Sailuotong or SLT, showed measurable improvements in memory and mental flexibility among people diagnosed with mild cognitive impairment—a condition that sits between normal aging and dementia, and carries a fivefold increased risk of progressing to full dementia in some cases.
The 12-week study enrolled 78 participants aged 60 and older, all with a diagnosis of mild cognitive impairment. Half received 180 milligrams daily of SLT in capsule form; the other half received a placebo. Neither the participants nor the researchers knew who was getting what. When the trial ended, those taking SLT showed statistically significant improvements in delayed memory recall—the ability to retrieve information after a delay—compared to the placebo group. They also performed better on tests of executive function, the mental processes involved in switching between tasks, dividing attention, and managing complex cognitive demands. The extract was well-tolerated, with few adverse events reported.
Sailuotong is a standardized herbal preparation combining extracts of Panax ginseng, Ginkgo biloba, and Crocus sativus, commonly known as saffron. It was developed through a collaboration between the NICM Health Research Institute in Sydney and the Xiyuan Hospital at China's Academy of Chinese Medical Sciences. The compound is thought to work through multiple mechanisms: reducing inflammation, combating oxidative stress, preventing cell death, and enhancing the brain's use of acetylcholine, a neurotransmitter critical to memory and attention.
The significance of these findings lies partly in what currently does not exist. Mild cognitive impairment has no approved pharmaceutical treatment. The medications available for Alzheimer's disease are not considered safe or effective for people at the earlier MCI stage. Yet the condition affects roughly 17 percent of people over 60 worldwide—a population measured in hundreds of millions. Early intervention is considered crucial; slowing or halting the progression from MCI to dementia could have enormous public health implications.
Associate Professor Genevieve Steiner-Lim, who led the trial, emphasized that even a 12-week intervention producing measurable cognitive gains is noteworthy. "Early intervention is critical in order to delay or prevent a dementia diagnosis," she said. The results, published in Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, a journal of the Alzheimer's Association, represent what the researchers frame as a promising first step rather than a finished answer.
The team acknowledges significant limitations. The trial was small and short. It measured cognitive performance on standardized tests but did not track whether improvements translated to better functioning in daily life—whether people could remember appointments more reliably, manage finances more effectively, or maintain independence longer. The researchers are now seeking funding for a larger, longer trial to determine whether SLT can sustain cognitive benefits over months or years, and whether it might genuinely delay or prevent the onset of dementia. Without that evidence, SLT remains a candidate worth investigating, not yet a treatment ready for widespread use.
Citas Notables
People with mild cognitive impairment have an increased risk of dementia—over fivefold in some cases—and at the moment we do not have any approved medications for mild cognitive impairment.— Associate Professor Genevieve Steiner-Lim, NICM Health Research Institute
Early intervention is critical in order to delay or prevent a dementia diagnosis.— Associate Professor Genevieve Steiner-Lim
La Conversación del Hearth Otra perspectiva de la historia
Why does it matter that this is a herbal extract rather than a synthesized drug?
Partly because there's no approved pharmaceutical for this condition at all. But also because herbal medicines work differently—they contain multiple active compounds, not just one. That complexity can be a liability in drug development, but it might also mean the extract addresses multiple pathways involved in cognitive decline simultaneously.
The trial was only 12 weeks. How much can you really learn in that timeframe?
You can learn whether something is safe and whether it produces measurable changes in the short term. That's what a phase II pilot trial is designed to do. But you're right to be skeptical about long-term benefit. The real question—does this actually slow someone's progression to dementia?—requires years of follow-up.
Seventeen percent of people over 60 have mild cognitive impairment. That's a huge population. Why hasn't this been solved already?
Because MCI is heterogeneous. Not everyone with it progresses to dementia. Some people stay stable for years. That makes it hard to design trials and hard to know if a treatment is actually working or if you're just looking at natural variation.
The researchers mention this was a collaboration with a Chinese hospital. Does that change how you read the results?
It shouldn't, if the trial was conducted rigorously and published in a reputable journal. But it's worth noting that the herbal extract itself comes from traditional Chinese medicine. That's where the scientific interest originated—not from a pharmaceutical company looking for a new market.
What happens next?
They need money for a bigger trial with more participants and a longer follow-up period. They need to measure not just test scores but whether people actually function better in their lives. And they need to figure out which patients benefit most—because not everyone with MCI is the same.